Advanced

Factor VIII therapy for hemophilia A: current and future issues

Aledort, Louis; Ljung, Rolf LU ; Mann, Kenneth and Pipe, Steven (2014) In Expert Review of Hematology 7(3). p.373-385
Abstract
Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
factor concentrate, FVIII, gene therapy, genetics, hemophilia A, immunogenicity, longer, acting FVIII, prophylaxis
in
Expert Review of Hematology
volume
7
issue
3
pages
373 - 385
publisher
Informa Healthcare
external identifiers
  • wos:000337290300008
  • scopus:84900839290
ISSN
1747-4086
DOI
10.1586/17474086.2014.899896
language
English
LU publication?
yes
id
dd7ca7dc-2542-45a2-9926-9f88df5f56c8 (old id 4544984)
date added to LUP
2014-08-01 07:36:23
date last changed
2017-11-12 03:01:51
@article{dd7ca7dc-2542-45a2-9926-9f88df5f56c8,
  abstract     = {Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.},
  author       = {Aledort, Louis and Ljung, Rolf and Mann, Kenneth and Pipe, Steven},
  issn         = {1747-4086},
  keyword      = {factor concentrate,FVIII,gene therapy,genetics,hemophilia A,immunogenicity,longer,acting FVIII,prophylaxis},
  language     = {eng},
  number       = {3},
  pages        = {373--385},
  publisher    = {Informa Healthcare},
  series       = {Expert Review of Hematology},
  title        = {Factor VIII therapy for hemophilia A: current and future issues},
  url          = {http://dx.doi.org/10.1586/17474086.2014.899896},
  volume       = {7},
  year         = {2014},
}